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Phosphorus and coronary
calcification in predialysis patients
To the Editor:We have read the interesting paper of Dr Chiu
et al.1 In a large cohort of proteinuric chronic kidney disease
(CKD) patients with diabetic nephropathy, the authors found
an association between coronary artery calciﬁcation (CAC)
score and risk of death, but they were unable to demonstrate
that CAC score was signiﬁcantly associated to (1) estimated
glomerular ﬁltration rate (eGFR), (2) variables that measure
mineral metabolism and inﬂammation, (3) dyslipidemia. A
similar lack of association between the above variables and
CAC has been previously reported even in non-diabetic CKD
patients (stages 3–5), in whom older age was the unique
predictor factor of CAC.2,3 Taken together, these studies may
indicate that phosphorus is marginally or not at all involved
in the process leading to calciﬁcation. The role of phosphorus
in CAC of CKD patients is ambiguous. On evaluating CAC
progression and its effects on survival, we found that CKD
patients who were not on dialysis and had ‘high–normal’
serum phosphorus levels had faster progression of CAC and
worse survival;3 progression might be slowed down by
phosphorus-binding therapy in the absence of changes in
serum phosphorus concentration.4
More likely, serum phosphorus concentration tells us little
about its balance. In addition, the calciﬁcation process takes a
longer time, while its potential causal factors (particularly
mineral metabolism) rapidly change over time for compen-
satory mechanisms that are mostly active in the early stages of
CKD. Correlating such a long-lasting process with rapidly
ﬂuctuating variables may explain the lack of association.
In the ﬁeld of vascular calciﬁcation, an indicator (such as
glycosylated hemoglobin in diabetics) that gives reliable
information on past ﬂuctuations of the variables that are
potentially involved in the pathogenesis of CAC is needed.
1. Chiu YW, Adler SG, Budoff MJ et al. Coronary artery calcification and
mortality in diabetic patients with proteinuria. Kidney Int 2010; 77:
1107–1114.
2. Russo D, Palmiero G, De Blasio AP et al. Coronary artery calcification in
patients with chronic renal failure not undergoing dialysis. Am J Kidney Dis
2004; 44: 104–1030.
3. Russo D, Corrao S, Miranda I et al. Progression of coronary artery
calcification in predialysis patients. Am J Nephrol 2007; 27: 152–158.
4. Russo D, Miranda I, Ruocco C et al. The progression of coronary artery
calcification in predialysis patients on calcium carbonate or sevelamer.
Kidney Int 2007; 72: 1255–1261.
Domenico Russo1, Yuri Battaglia1 and Elisa Buonanno1
1Department of Nephrology, University Federico II, Cardito, Italy
Correspondence: Domenico Russo, Department of Nephrology, University
Federico II, via G Marconi, 80, Cardito 80024, Italy.
E-mail: domenicorusso51@hotmail.com
Kidney International (2010) 78, 818; doi:10.1038/ki.2010.307
The Authors Reply: We appreciate Russo et al.,1 for their
insightful remarks and for pointing out the apparent
discrepancy between in vitro and animal studies and that in
humans. Thus, on one hand, cell culture and animal studies
have ﬁrmly established a pivotal role for phosphorus (P) in
the active cell-mediated process of vascular calciﬁcation.2 On
the other hand, as Russo et al.,1 point out, most observational
studies in chronic kidney disease patients have been unable
to show an association between serum P and vascular
calciﬁcation.3,4 Russo et al.,1 rightly urge caution, as a single
measurement of serum P does not provide any information
on the life-time exposure in a given individual. However, we
wish to draw attention to another important issue—the
P present in the blood is o1% of the total body P. It
is conceivable that—though presently not known—an
individual may achieve a signiﬁcant positive P balance
without a signiﬁcant change in its serum levels. P binder
may mitigate the positive P balance without changing serum
P levels—it may be for this reason that they were able to
attenuate vascular calciﬁcation. Notwithstanding the limita-
tions of serum P, the importance of P in inducing or
worsening vascular calciﬁcation in humans can be deﬁnitively
answered only by interventional studies, in which subjects are
randomized to two different levels of serum P.
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